/
KLRS
$4.22-$0.11 (-2.43%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$102.8M
24M shares
52-week range
$2.14 – $11.88
21% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
1.91%
Moderate
Price (6 mo)
Loading chart…
Change$-7.26
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $165.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $73.0K | $1.1M | $0 | $0 | $0 | $13.0K |
| Gross profit | $0 | $0 | −$73.0K | −$1.1M | $0 | $0 | $0 | −$13.0K |
| Gross margin | 0.0% | 0.0% | — | — | — | — | — | — |
| R&D | $1.7M | $16.2M | $49.6M | $119.6M | $11.8M | $11.7M | $12.3M | $30.8M |
| Operating income | −$3.6M | −$26.7M | −$71.3M | −$169.8M | −$14.0M | −$13.5M | −$55.3M | −$46.2M |
| EBITDA | −$2.4M | −$23.8M | −$69.7M | −$169.8M | −$15.3M | −$14.0M | −$58.8M | −$42.0M |
| Net income | −$2.4M | −$23.8M | −$69.8M | −$172.0M | −$15.5M | −$14.7M | −$58.8M | −$43.4M |
| Net margin | -214.1% | -14447.9% | — | — | — | — | — | — |
| EPS (diluted) | -2.88 | -8.42 | -59.67 | -63.00 | -50.62 | -42.09 | -11.73 | -2.85 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-2.03 | $-2.22–$-1.64 | 6 |
| 2027 | $10M | $-1.63 | $-1.79–$-1.41 | 7 |
| 2028 | $0 | $-2.28 | $-3.83–$-1.32 | 6 |
| 2029 | $4M | $-2.56 | $-2.56–$-2.56 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$6.25
Price
$4.21
Implied upside
+48%
Peer comparison
Kalaris Therapeutics, Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
www.kalaristx.com- Employees
- 20
- IPO / List date
- Mar 19, 2025
- HQ
- BERKELEY HEIGHTS, NJ
Held by traders on TradeandTell
No one on the platform currently holds KLRS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 66,151 | $381.7K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded KLRS yet.
